companytechnologyproductsservicesabout uscontact


Particle Therapeutics today announced the appointment of Mike Adlam as the Company’s new CEO.

Mike worked for Amersham plc (now GE Healthcare) between 1976 and 2006. He played a key role in the development of Amersham in a number of senior management posts and became Executive Vice President Bioscience Operations. Since 2006, Mike has acted as a consultant to GE Healthcare. Mike has extensive experience negotiating at a senior level in the regulatory fields of nuclear operations and pharmaceutical manufacturing in Europe and the USA. He has wide experience of GMP pharmaceutic manufacturing. He has also acquired qualifications in finance and accounting and an MBA.

Fred Cornhill, the Company’s Executive Director, commenting on Mike Adlam’s appointment, said: “Mike Adlam brings to Particle Therapeutics a wealth of operational experience in the pharmaceutical field. His experience in manufacturing and regulatory affairs will be of particular benefit to a start up company like Particle Therapeutics as it moves toward clinical studies in the next 24 months.”

Mike Adlam, commenting on his appointment, said: “I am extremely excited by the challenge of leading Particle Therapeutics and somewhat humbled by the expertise, creativity and professionalism of the team I have working with me. We are all very much focussed on successfully achieving the first key milestone for our lead product – glucagon – and then driving forward to preclinical and clinical studies.”

Mike will take up his new position with Particle Therapeutics on October 15, 2007.